Skip to content
Clinical Trials – home
Not yet recruiting

Phase 2 Open‑Label Trial Assessing Safety and Efficacy of Nebaprubart in Adults with IgA‑Mediated Renal Diseases

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on adults who have kidney problems caused by an abnormal immune protein called IgA. These conditions include lupus nephritis, IgA nephropathy, and IgA vasculitis nephritis, which can lead to blood or protein appearing in the urine and may gradually damage kidney function. The medication being tested is Nebaprubart (code name JJP-1212), which is given by an intravenous (through a vein) infusion, meaning the drug is slowly dripped into the bloodstream.

The purpose of the study is to assess the safety, tolerability and how well the drug works in these kidney diseases. Participants will receive a series of infusions over several months, with regular check‑ups that include blood tests (such as serum creatinine, a measure of kidney function), urine collections to calculate the urine protein to creatinine ratio (a way to see how much protein is lost in the urine), heart rhythm recordings (ECG), and physical examinations. Researchers will also look for any anti‑drug antibodies, which are signs that the body’s immune system is reacting to the medicine, and will record any adverse events, meaning any unwanted side effects that occur during the trial.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Assessment

    After enrollment, you will undergo a comprehensive baseline assessment that includes a physical examination, measurement of vital signs (such as blood pressure and heart rate), and collection of blood and urine samples for laboratory tests.

    An electrocardiogram (ECG) will be performed to record the electrical activity of your heart, and a blood test will measure serum creatinine to evaluate kidney function.

    All findings will be recorded before the first dose of the study medication.

  2. Step 2

    First Nebaprubart Infusion

    You will receive nebaprubart as an intravenous infusion. The exact dose and volume are defined by the study protocol and will be prepared by the clinical staff.

    The infusion will be administered through a vein over a period specified in the protocol, and the infusion site will be monitored throughout the procedure.

  3. Step 3

    Monitoring for Infusion‑Related Reactions

    Immediately after the infusion, medical personnel will observe you for any infusion‑related reactions (IRRs), such as fever, chills, rash, or breathing difficulties.

    Vital signs will be checked regularly during this observation period, and any adverse symptoms will be documented and managed according to the study safety guidelines.

  4. Step 4

    Scheduled Follow‑Up Visits and Additional Infusions

    You will attend regular follow‑up visits according to the schedule defined in the protocol, which may be weekly, bi‑weekly, or monthly.

    During each visit, additional nebaprubart infusions will be given if required by the study design. The frequency and total duration of treatment are specified in the protocol and may continue for several months.

  5. Step 5

    Ongoing Safety Laboratory and Clinical Evaluations

    At each follow‑up visit, blood and urine samples will be collected to assess laboratory tests such as hematology, blood chemistry, and urinalysis.

    Serum creatinine will be measured to track changes in kidney function, and the 24‑hour urine protein‑to‑creatinine ratio will be calculated to evaluate protein loss in the urine.

    An ECG may be repeated at predetermined intervals to monitor heart health, and vital signs will be recorded at every visit.

  6. Step 6

    End‑of‑Treatment Evaluation

    When the planned treatment period ends, a final assessment will be performed. This includes a complete set of laboratory tests, ECG, and measurement of serum creatinine and urine protein levels.

    Blood will also be tested for the presence of anti‑drug antibodies (ADAs) to determine whether your immune system has responded to the medication.

  7. Step 7

    Post‑Treatment Follow‑Up

    After the last dose, you will continue to be monitored for a defined follow‑up period to capture any delayed adverse events.

    During this time, occasional clinic visits or phone contacts may be arranged to record any new symptoms, repeat selected laboratory tests, and ensure your safety.

Who can join the trial?

16 criteria

  • Provide a signed informed consent form before any study procedures are done, meaning you agree to take part after understanding what will happen.
  • Be between 18 and 75 years old, have a body‑mass index (BMI) from 18.5 to 32, and weigh at least 45 kg but no more than 109 kg.
  • Have a kidney biopsy that confirms the specific kidney disease you have.
  • If you are a woman who could become pregnant and are sexually active, you must have a negative pregnancy test and use a highly effective birth‑control method during the study and for four months after the last dose.
  • If you are a man who is not sterilized and have a partner who could become pregnant, you must use a condom with spermicide and your partner must also use a highly effective birth‑control method during the study and for four months after the last dose.
  • Be able to understand the study, give consent, and agree to follow all study requirements.
  • For IgA nephropathy (IgAN) or IgA vasculitis nephritis (IgAV‑N), have a confirmed diagnosis based on a kidney biopsy done before or during screening.
  • For IgAN or IgAV‑N, have a urine protein‑to‑creatinine ratio (UPCR) that meets the study’s specified level; this test measures how much protein is in your urine.
  • For IgAN or IgAV‑N, have an estimated glomerular filtration rate (eGFR) that meets the study’s specified level; eGFR estimates how well your kidneys are filtering waste.
  • For IgAN or IgAV‑N, have stable blood pressure that is lower than 140/90 mm Hg for at least three months before joining the study.
  • For IgAN or IgAV‑N, be on a stable, maximum‑tolerated dose of a renin‑angiotensin system (RAS) inhibitor—either an ACE inhibitor or an angiotensin receptor blocker (ARB)—for at least 90 days, and either be taking a SGLT2 inhibitor at a stable dose for at least 90 days or have a documented reason for not taking it; no changes to these medicines are allowed during the study.
  • For lupus nephritis (LN), have a clinical diagnosis of systemic lupus erythematosus (SLE) based on the 2019 criteria from the American College of Rheumatology and the European League Against Rheumatism.
  • For LN, have a kidney biopsy taken within six months that shows active class III or IV disease (or both class III/IV and class V), with the pathology report confirming the classification and activity level.
  • For LN, have clinically active disease that requires or is receiving immunosuppressive therapy as judged by the investigator.
  • For LN, have a urine protein‑to‑creatinine ratio (UPCR) that meets the study’s specified level.
  • For LN, have an estimated glomerular filtration rate (eGFR) that meets the study’s specified level, calculated using the 2021 CKD‑EPI Creatinine‑Cystatin equation (a formula used to estimate kidney function).

Who cannot join the trial?

36 criteria

  • Having another chronic kidney disease that is not one of the study’s IgA‑related kidney diseases.
  • Having a significant kidney disease other than the study diseases (for example, diabetic kidney disease or membranous nephropathy) shown on a recent kidney biopsy (high‑blood‑pressure changes in the kidney are allowed).
  • Having nephrotic syndrome, which means large amounts of protein in the urine, swelling, and low blood protein levels.
  • Being diagnosed with Type 1 diabetes.
  • Having uncontrolled Type 2 diabetes, shown by a blood‑sugar test (HbA1c) higher than 8 % (64 mmol/mol).
  • Having uncontrolled high blood pressure (systolic over 160 mm Hg or diastolic over 100 mm Hg).
  • Having a chronic autoimmune neuro‑degenerative disorder such as multiple sclerosis.
  • Having any other serious disease that could make the study unsafe or affect the results (for example, immune deficiency, major heart, lung, liver, stomach, blood‑clotting, or mental‑health problems, or conditions that change how medicines are absorbed or cleared).
  • Having been on dialysis in the past 12 months or being expected to need dialysis or a kidney transplant within the next 12 months.
  • Having a positive pregnancy test or currently breastfeeding (women only).
  • Women using hormone replacement therapy unless they stop it at least 4 weeks before enrollment and use a highly effective birth‑control method.
  • Receiving a live or weakened (attenuated) vaccine within 1 month before enrollment and until the end of the study.
  • Having an active infection or a serious infection within the past month.
  • Having a history of cancer, except for certain skin cancers or cancers that were treated curatively and have shown no return for at least 5 years.
  • Having a positive or unclear tuberculosis (TB) test (QuantiFERON) within 35 days before the first dose.
  • Having had a bone‑marrow or solid‑organ transplant.
  • Having taken part in any previous JJP‑1212 studies.
  • Being a vulnerable participant such as an incarcerated person.
  • Being a close relative of, or directly involved with, any trial staff.
  • Having recent minor medical problems that the investigator feels could interfere with study data or the ability to follow study procedures.
  • Having certain kidney‑biopsy findings for IgA nephropathy or IgA‑vasculitis (MEST‑C score of T2 or C2, more than 50 % tubulointerstitial scarring, or crescents in more than 25 % of glomeruli).
  • Having kidney‑function levels (eGFR) that do not meet the specific limits set by the study for IgA nephropathy, IgA‑vasculitis, or lupus nephritis.
  • Being diagnosed with rapidly progressive glomerulonephritis (a fast‑moving kidney inflammation) as defined by the study.
  • Having a secondary form of the disease (for example, minimal change disease with IgA deposits, infection‑related IgA nephropathy, or liver‑cirrhosis‑related IgA nephropathy).
  • Having used any of the following immune‑modifying medicines within the prior 12 weeks: immunoglobulin therapy; calcineurin inhibitors (such as cyclosporin, voclosporin, or tacrolimus); mTOR inhibitors; retinoids; thalidomide or lenalidomide; Janus‑kinase (JAK) inhibitors; high‑dose IV cyclophosphamide (more than 2 pulses of ≥0.5 g/m²) or low‑dose cyclophosphamide (more than 4 doses of 500 mg every 2 weeks); other alkylating agents (e.g., chlorambucil); cytokine or cytokine‑receptor blockers; belimumab, abatacept, or eculizumab; or any other biologic drugs used for immunosuppression.
  • Having used B‑cell‑depleting therapies (such as rituximab, ocrelizumab, ofatumumab, inebilizumab, telitacicept, atacicept, or obinutuzumab) or systemic steroids for more than 2 weeks for any illness in the past 24 weeks.
  • Having taken systemic corticosteroids at a dose higher than 20 mg per day of prednisone (or equivalent) for more than 14 consecutive days, or other systemic immunosuppressive drugs, within 6 months before screening (unless they are stable background kidney‑directed therapies allowed by the protocol).
  • Having abnormal laboratory results at screening, such as: liver enzymes (AST or ALT) more than 2.5 times the upper limit of normal; total bilirubin more than 1.5 times normal (unless due to Gilbert’s syndrome); platelet count less than 50,000 /µL (or less than 25,000 /µL if due to active lupus); hemoglobin less than 8 g/dL (or less than 7 g/dL if due to active lupus); or total lymphocyte count less than 200 cells/mm³.
  • Having low immunoglobulin levels: IgG ≤ 700 mg/dL, IgM ≤ 40 mg/dL, or IgA ≤ 70 mg/dL.
  • Testing positive for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody (HCVAb), or HIV.
  • Having clinically important abnormalities on a standard 12‑lead electrocardiogram (ECG) as judged by the investigator.
  • Having a known or suspected history of drug abuse in the past year, as judged by the investigator.
  • Having a history of drug or alcohol abuse or excessive alcohol intake within the past year, as judged by the investigator.
  • Testing positive for alcohol use at the screening visit before the first dose.
  • Needing to stop certain medicines (methotrexate, azathioprine, leflunomide, mizoribine, or cholestyramine) before the enrollment day if taking mycophenolate mofetil (MMF) because of possible drug interactions.
  • Having only one kidney or a functionally single kidney (including congenital absence, prior removal, severe shrinkage, or other conditions leaving only one working kidney).
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Nebaprubart is an experimental medicine that is given through an IV (intravenous) infusion. It is a liquid concentrate that is mixed with a solution before being administered. In this trial, the drug is being tested in adults who have kidney problems caused by abnormal IgA antibodies, such as lupus nephritis, IgA nephropathy, or IgA‑related vasculitis kidney disease. The main goal is to see whether Nebaprubart is safe to use, how well patients can tolerate it, and whether it helps improve kidney function in these conditions. Because it is an orphan drug, it is being studied for a disease area that has few treatment options.

What is already known about the treatment

Nebaprubart - Nebaprubart is given by intravenous infusion as a concentrate that is mixed with fluid and delivered into a vein. It is currently an experimental orphan drug being studied in a Phase 2 basket trial and is not yet approved for routine medical use. The drug is being tested for adults with IgA‑mediated kidney diseases such as IgA nephropathy, lupus nephritis, and IgA‑vasculitis nephritis. It works by blocking a specific protein that drives inflammation in the kidney, helping to reduce damage, and it is classified as an investigational biologic agent for renal disease.

Investigated diseases

  • Lupus nephritis

    It is kidney inflammation caused by systemic lupus erythematosus. The immune system attacks the kidney’s filtering units, leading to swelling and damage. Over time, protein may leak into urine and kidney function can gradually decline. Flare-ups can increase inflammation, while periods of lower activity may have fewer symptoms. The disease can affect both kidneys and may become chronic if not controlled.

  • IgA nephropathy

    It is a kidney condition where deposits of the antibody IgA build up in the glomeruli. These deposits cause inflammation and scarring of the filtering structures. As the scarring progresses, protein and blood may appear in the urine and kidney function can slowly worsen. Episodes of increased blood in urine often follow infections of the throat or gut. The disease can remain stable for years or advance gradually.

  • IgA vasculitis with nephritis

    This disorder involves inflammation of small blood vessels throughout the body, accompanied by IgA deposits in the kidneys. The kidney involvement leads to swelling, blood and protein in the urine, and gradual loss of filtering ability. Skin rash, joint pain, and abdominal pain may appear before kidney signs. Kidney damage can increase over time, especially after repeated episodes of vessel inflammation. The condition may persist or improve, but kidney changes can become permanent.

Trial detailsLast updated 19 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-527194-11-00Protocol codeJJP-1212-02-01Estimated enrolment21 patientsSponsorJJP BIOLOGICS Sp. z o.o.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.